Neuren Pharmaceuticals Ltd (ASX: NEU) Share Price and News

Price

$12.43

Movement

0.41 (+3.41%)

as at 13 May 11:29am (20 mins delayed)

52 Week Range

$8.61 - $24.00

 
1 Year Return

-34.78%

Neuren Pharmaceuticals Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $1.50 billion
P/E Ratio 11.62
Dividend Yield 0.00%
Shares Outstanding 127.15 million
Earnings per share 1.086
Dividend per share N/A
Year To Date Return 6.32%
Earnings Yield 8.61%
Franking -
Share Price

$12.43

Day Change

0.41 (+3.41%)

52 Week Range

$8.61 - $24.00

Yesterday's Close

$12.02

Today's Open

$12.51

Days Range

$12.27 - $12.62

Volume

298,915

Avg. Volume (1 month)

772,113

Turnover

$3,719,586

as at 13 May 11:29am

  • Neuren Pharmaceuticals Ltd (ASX: NEU)
    Latest News

    A man in a white coat holds a laptop in one hand and his head in the other, it's bad news.
    Healthcare Shares

    Why is this ASX 200 pharmaceuticals stock crashing 15% today?

    Investors haven't responded positively to a sales update.

    Read more »

    A neon sign says 'Top Ten'.
    Share Gainers

    Here are the top 10 ASX 200 shares today

    It was a mildly positive start to the trading week for ASX shares today.

    Read more »

    a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
    Growth Shares

    A hot ASX stock with 'multiple catalysts' looming is 8% down. Time to buy

    The Blackwattle team is still bullish on these pharmaceutical shares despite a recent sell-off.

    Read more »

    A young man clasps his hand to his head with his eyes closed and a pained expression on his face as he clasps a laptop computer in front of him, seemingly learning of bad news or a poor investment.
    Share Fallers

    Why Inghams, IAG, Neuren Pharmaceuticals, and Pro Medicus shares are sinking today

    These ASX shares are ending the week deep in the red. But why?

    Read more »

    Shot of a senior scientist looking stressed out while working in a lab.
    Healthcare Shares

    This ASX 200 healthcare share is diving 13% as short sellers take aim

    A short seller is describing this company's Daybue product as a 'flop'.

    Read more »

    Male Lab Worker Wearing White Coat Recording Test Results On Computer.
    Share Gainers

    If you'd put $20,000 in this ASX healthcare stock in December 2021, you'd have $257,000 now

    In just over 2 years, these shares have gone gangbusters, allowing its investors to forget about the losses made by…

    Read more »

    Three hikers lift their arms in jubilation as they reach a rocky peak overlooking a sensational view of water and mountains with a blue sky surrounding them.
    Best Shares

    Top ASX shares to buy in February 2024

    The Aussie stock market is scaling new heights. Are you getting in on the action?

    Read more »

    A young girl looks up and balances a pencil on her nose, while thinking about a decision she has to make.
    Investing Strategies

    Is now the right time to buy this ASX 200 stock? Here's my take

    These shares are up 163% over the past year. Is it too late to add to your portfolio?

    Read more »

    Three health professionals at a hospital smile for the camera.
    Healthcare Shares

    3 pharma shares outshining the ASX index today

    The ASX All Ords finished lower on Friday but these three stocks outdid their peers.

    Read more »

    A man with a wide, eager smile on his face holds up three fingers.
    Growth Shares

    'Materially undervalued': 3 ASX shares Elvest is backing for a huge 2024

    Here is a trio of growth stocks that finished 2023 with much fanfare but have plenty left in the tank…

    Read more »

    Happy, tablet or doctor in a laboratory with research results or positive feedback after medical data analysis. Smile, vaccine or healthcare worker reading or working on futuristic science innovation.
    Healthcare Shares

    The Neuren Pharmaceuticals share price is up 100% in 3 months: Can it keep rising?

    This pharma share had a transformational year in 2023. Where next for its shares?

    Read more »

    Smiling woman upside down on a swing with yellow glasses, symbolising passive income.
    Investing Strategies

    Here's how I plan to build a second income in 2024

    An additional source of cash is what many aspire to when ploughing our money into ASX shares.

    Read more »

    Frequently Asked Questions

    NEU ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size

    About Neuren Pharmaceuticals Ltd

    Neuren Pharmaceuticals Limited (ASX: NEU) is a biopharmaceutical company specialising in developing new therapies for neurodevelopmental disorders that emerge in early childhood and are characterised by impaired connections and signalling between brain cells. 

    In March 2023, the US Food and Drug Administration approved DAYBUE™ (trofinetide) for the treatment of Rett syndrome in adults and children two years and older. Neuren's US partner Acadia Pharmaceuticals (NASDAQ: ACAD) holds a worldwide exclusive licence from Neuren for trofinetide. At this time, DAYBUE is the first and only drug approved for the treatment of Rett syndrome. Trofinetide has also demonstrated clinical benefit in a Phase 2 trial in treating Fragile X syndrome.

    Neuren's second product NNZ-2591 is currently in Phase 2 clinical trials for the treatment of Phelan-McDermid syndrome, Angelman syndrome, Pitt Hopkins syndrome, and Prader-Willi syndrome. The drug candidate has shown positive effects in mouse models of each syndrome and was successful in a Phase 1 clinical trial. The number of patients across these four disorders is estimated as five times the number of Rett syndrome patients. There are currently no drugs approved for these conditions, apart from growth hormone to treat some aspects of Prader-Willi. 

    Acadia Pharmaceuticals also holds a worldwide exclusive licence to develop and commercialise NNZ-2591 for Rett syndrome and Fragile X syndrome. Neuren retains worldwide rights to NNZ-2591 in all other indications.

    NEU Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    12 May 2025 $12.02 $-1.27 -9.56% 1,490,963 $12.89 $12.89 $11.97
    09 May 2025 $13.29 $0.49 3.83% 757,061 $13.19 $13.49 $12.81
    08 May 2025 $12.80 $0.18 1.43% 1,193,552 $12.60 $12.89 $12.11
    07 May 2025 $12.62 $0.47 3.87% 752,028 $12.05 $12.70 $12.03
    06 May 2025 $12.15 $-0.15 -1.22% 359,857 $12.30 $12.51 $12.13
    05 May 2025 $12.30 $-0.14 -1.13% 630,459 $12.60 $12.73 $12.10
    02 May 2025 $12.44 $0.64 5.42% 606,889 $11.74 $12.79 $11.67
    01 May 2025 $11.80 $0.14 1.20% 455,202 $11.70 $11.98 $11.61
    30 Apr 2025 $11.66 $0.10 0.87% 608,951 $11.65 $11.72 $11.36
    29 Apr 2025 $11.56 $0.57 5.19% 677,157 $11.00 $11.62 $10.92
    28 Apr 2025 $10.99 $-0.35 -3.09% 560,080 $11.43 $11.59 $10.99
    24 Apr 2025 $11.34 $0.33 3.00% 493,618 $11.16 $11.59 $11.16
    23 Apr 2025 $11.01 $0.62 5.97% 550,515 $10.81 $11.27 $10.61
    22 Apr 2025 $10.39 $-0.14 -1.33% 458,821 $10.45 $10.67 $10.32
    17 Apr 2025 $10.53 $0.36 3.54% 672,718 $10.11 $10.53 $10.11
    16 Apr 2025 $10.17 $-0.81 -7.38% 852,200 $10.86 $10.95 $10.10
    15 Apr 2025 $10.98 $-0.15 -1.35% 1,102,530 $11.20 $11.63 $10.51

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    16 Apr 2025 Joseph(Joe) Basile Buy 14,500 $153,158
    On-market trade.
    16 Aug 2024 Joseph(Joe) Basile Buy 6,406 $100,766
    On-market trade.
    11 Jun 2024 Joseph(Joe) Basile Buy 5,000 $97,450
    On-market trade.

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Ms Dianne Margaret Angus Non-Executive Director Jul 2018
    Ms Angus has executive managerial and company director experience in the biotechnology, biopharmaceutical, medical device, agritech and healthcare industries. Dianne has created global industry partnerships to yield medical, pharmaceutical and agricultural products. She has also driven the development path for novel neurological pre-clinical agents to late stage clinical assets before the FDA and European regulators. With over twenty five year' experience in ASX and NASDAQ listed companies, she has experience in business development, capital raising and investor relations together with corporate governance and compliance capabilities. She is also a council member of Deakin University.
    Mr Jonathan (Jon) Charles Pilcher Chief Executive OfficerManaging Director Aug 2013
    Mr Pilcher has played a central role in all aspects of Neuren's R&D, commercial and corporate activities. Before joining Neuren he was a member of the leadership team at Acrux throughout a period that included Acrux's IPO and listing on the ASX, the development and FDA approval of three novel pharmaceutical products and a transforming licensing deal with Eli Lilly in 2010. He formerly spent seven years in a series of executive positions in the R&D and corporate functions of international pharmaceutical groups Medeva and Celltech, which are now part of UCB.
    Dr Jenny Lee Harry Non-Executive Director Jul 2018
    Dr Harry has 20 years' experience in executive management of companies in the biotechnology and biopharmaceutical industry and is an accomplished CEO and Managing Director with experience in growing companies from start-up to commercialisation. She has served on Boards of a number of listed and unlisted companies and is currently a Non-Executive Director of Lumitron Technologies Inc.
    Mr Patrick Davies Non-Executive DirectorNon-Executive Chairman Jul 2018
    Mr Davies has held executive management roles in the Australian and New Zealand healthcare industry for over twenty five years having performed in senior roles across industry sectors including pharmacy, primary care, pharmaceutical and consumer products. During his ten year period as Chief Executive Officer of EBOS Group Limited (and previously Symbion), the enterprise value of the group achieved compound annual growth in enterprise value of +20% (from circa $450M to in excess of $3.1B). He is a director on other corporate boards and provides strategic advice to a range of healthcare businesses and investors.
    Mr Joseph(Joe) Basile Non-Executive Director Mar 2023
    Mr Basile has held a number of executive roles in the pharmaceutical industry for over 30 years, most recently as Group CFO at iNova Pharmaceuticals based in Singapore and prior to that with Novartis in senior Finance leadership and Commercial Sales leadership roles in Australia and Asia.
    Ms Lauren Frazer Chief Financial OfficerCompany Secretary Aug 2020
    -
    Gerry Zhao Chief Business Officer
    -
    Lauren Frazer Chief Financial OfficerCompany Secretary
    -
    Liza Squires Chief Medical Officer
    -
    Clive Blower Chief Operations Officer
    -
    Larry Glass Chief Science Officer
    -

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    HSBC Custody Nominees (Australia) Limited 17,684,031 13.97%
    Citicorp Nominees Pty Limited 13,225,277 10.45%
    J P Morgan Nominees Australia Pty Limited 12,906,867 10.20%
    Cameron Richard Pty Ltd 4,355,222 3.44%
    BNP Paribas Noms Pty Ltd 4,056,178 3.20%
    Stuart Andrew Pty Ltd 2,790,348 2.20%
    Essex Castle Limited 2,322,678 1.83%
    Linwierik Super Pty Ltd 1,800,000 1.42%
    Smithley Super Pty Ltd 1,584,000 1.25%
    Sharesies Australia Nominee Pty Limited 1,497,609 1.18%
    National Nominees Limited 1,143,545 0.90%
    First Colbyco Pty Ltd 829,200 0.65%
    BNP Paribas Nominees Pty Ltd 765,775 0.60%
    Dr Robin Lance Congreve 671,637 0.53%
    Mjhft Pty Ltd 600,000 0.47%
    Netwealth Investments Limited 560,073 0.44%
    Custodial Services Limited 554,271 0.44%
    HSBC Custody Nominees (Australia) Limited A/C 2 490,918 0.39%
    Emancipayte Pty Ltd 463,141 0.37%
    BNP Paribas Nominees Pty Ltd i 434,135 0.34%

    Profile

    since

    Note